Learning Stage
KAVITA JUNEJA, MD is an endocrinologist and industry physician with broad experience in endocrinology, liver disease, virology, and rare diseases. After several years of practicing as a clinician and study investigator in Austin, Juneja shifted to industry in 2016: first with Novo Nordisk (Marketing, South Texas) and then with Aegerion Pharmaceuticals (US Medical Director for metreleptin, Medical Affairs). She later relocated to the Bay Area to work on the Gilead Global Medical Affairs NASH team. In 2020, in light of the COVID-19 pandemic, she transitioned to the Development team to serve as the Global Development Lead for remdesivir, the first antiviral available for the treatment of COVID-19. She played a critical role in the development and regulatory strategy that broadened its access to millions across the globe. In 2022, Juneja returned to metabolic disease as the head of metabolic therapeutic development at Corcept Therapeutics, overseeing development of miricorilant, a selective glucocorticoid receptor modulator for the treatment of MASH (metabolic-associated steatohepatitis).